For research use only. Not for therapeutic Use.
BMS-986299 (compound 112) is a first-in-class NLRP3 inflammasome agonist with an EC50 of 1.28 μM. (patent WO2018152396A1).
BMS 986299 (1-1000 μM) shows low toxicity of cells PNRCMs[2].
BMS 986299 (1 μM, 1 h) upregulates the NLRP3 expression, stimulates the NLRP3 mediated cardiomyocyte pyroptosis in PNRCMs and therefore aggravates the DCM[2].
| Catalog Number | I044414 |
| CAS Number | 2242952-69-6 |
| Synonyms | N-[[4-amino-7-(1H-pyrazol-5-yl)-3H-imidazo[4,5-c]quinolin-2-yl]methyl]-N-ethylacetamide |
| Molecular Formula | C18H19N7O |
| Purity | ≥95% |
| InChI | InChI=1S/C18H19N7O/c1-3-25(10(2)26)9-15-22-16-12-5-4-11(13-6-7-20-24-13)8-14(12)21-18(19)17(16)23-15/h4-8H,3,9H2,1-2H3,(H2,19,21)(H,20,24)(H,22,23) |
| InChIKey | UHNRLQRZRNKOKU-UHFFFAOYSA-N |
| SMILES | CCN(CC1=NC2=C(N1)C(=NC3=C2C=CC(=C3)C4=CC=NN4)N)C(=O)C |
| Reference | [1]. Gary Glick, et al. Substituted imidazo-quinolines as nlrp3 modulators. WO2018152396A1. [2]. Gao G, et al., Cyclovirobuxine D Ameliorates Experimental Diabetic Cardiomyopathy by Inhibiting Cardiomyocyte Pyroptosis via NLRP3 in vivo and in vitro. Front Pharmacol. 2022 Jul 5;13:906548. |
